early stage lung cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)Age greater than 18 years old, male or female; 2)Patients with benign nodules, carcinoma in situ and stage I lung cancer diagnosed by histologic and/or cytologic examination; 3)Patients with single nodule in the lung; 4)The ability to obtain comprehensive clinical and pathologic information about them; 5) Subjects read and fully understood the patient instructions and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1)Patients with multiple nodules in the lungs; 2)Female population during pregnancy; 3)Current diagnosis of tumors other than lung cancer or previous history of tumors; 4)Received any form of oncologic therapy, including surgery, radiation/chemotherapy, targeted therapy, and immunotherapy prior to enrollment in the blood draw; 5) Those with a current febrile illness or who have had an acute exacerbation or flare-up of an inflammatory disease within 14 days prior to the blood draw that requires them to be under medical treatment; 6)Organ transplant recipients or people with prior non-autologous (allogeneic) bone marrow or stem cell transplantation; 7)People who are in poor health or unfit to have their blood drawn; 8) any other disease or condition of clinical significance that, in the opinion of the investigator, could affect adherence to the protocol, or affect the patient's ability to sign the informed consent form, or make participation in this clinical trial inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subject copy number changes;cfDNA fragment length;cfDNA fragment end motif;cfDNA fragment breakpoint motif; | — |
Countries
China
Contacts
Beijing Chao-Yang Hospital, Capital Medical University